Since its creation in 1988, OPALIA Pharma has established itself as one of the leaders in generic drugs in Tunisia. A pioneer in the African market since 1993, it is now present in more than 25 countries in Africa and the Middle East. In 2013, the international RECORDATI group, based in Milan and active in more than 150 countries, acquired 90% of the capital, giving rise to OPALIA RECORDATI, its Tunisian subsidiary and only African subsidiary.
OPALIA RECORDATI has successfully combined medical innovation, technological excellence, and social commitment. With more than 400 employees, it encourages creativity, learning, and skills development, particularly in the fields of digital technology and artificial intelligence, to transform the healthcare pathway and patient experience.
In this milestone year, the company is celebrating its 35th anniversary, a milestone that symbolizes the success of the Tunisian pharmaceutical industry, innovation, and hope. According to Dr. Alya El Hedda, General Manager, “Our goal is to unlock the potential of every individual’s life by offering cutting-edge healthcare solutions, while ensuring that treatments are accessible to all.” ”
Social responsibility and sustainability are also at the heart of its approach. OPALIA RECORDATI is reducing its environmental footprint and actively supporting local communities, demonstrating that economic prosperity and social commitment can go hand in hand.
Today, OPALIA RECORDATI is a source of inspiration for young Tunisians, promoting innovation, digital technology, and science to improve the health and well-being of all. Its 35th anniversary celebrates not only its history, but also a future focused on technology, education, and the transformation of the pharmaceutical industry in Tunisia and beyond.
Recordati Tunisia | Global
